Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients
Related Experiment Video
Updated: Jun 6, 2026

Static Strength Training Method for Type 2 Diabetic Mice
Published on: March 29, 2024
Arpita Chakraborty1, Subhankar Chowdhury, Maitree Bhattacharyya
1Department of Biochemistry, University of Calcutta, 35, Ballygunge Circular Road, Kolkata 700019, India.
Aim:
Advanced research has radically changed both diagnosis and treatment of diabetes during last three decades; a number of classes of oral antidiabetic agents are currently available for better glycemic control. Present study aims to evaluate the effect of metformin on different stress and inflammatory parameters in diabetic subjects.
Methods:
208 type 2 diabetes patients were randomly assigned for metformin and placebo.
Results:
Reactive oxygen species generation, advanced oxidation protein products (179.65±13.6, 120.65±10.5 μmol/l) and pentosidine (107±10.4, 78±7.6 pmol/ml) were found to be reduced by metformin treatment compared to placebo. On the other hand metformin administration enhanced total thiol and nitric oxide level (p<0.05). But nutrient level (Mg(+2), Ca(+2)) in plasma was not altered by the treatment. Significant restoration of C reactive protein (p<0.05) was noticed after metformin therapy. Metformin administration also improved Na(+)K(+)ATPase activity (0.28±0.08, 0.41±0.07 μmol Pi/mg/h) in erythrocyte membrane.
Conclusions:
This study explores that metformin treatment restores the antioxidant status, enzymatic activity and inflammatory parameters in type 2 diabetic patients. Metformin therapy improves the status of oxidative and nitrosative stress altered in type 2 diabetes. This study unfolds the cardio protective role of metformin as an oral hypoglycemic agent.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type II Diabetes I: Introduction
Psychoneuroimmunology: Diabetes and Cancer
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
